Metformin prevents tobacco carcinogen--induced lung tumorigenesis.
Activation of the mammalian target of rapamycin (mTOR) pathway is an important and early event in tobacco carcinogen-induced lung tumorigenesis, and therapies that target mTOR could be effective in the prevention or treatment of lung cancer. The biguanide metformin, which is widely prescribed for the treatment of type II diabetes, might be a good candidate for lung cancer chemoprevention because it activates AMP-activated protein kinase (AMPK), which can inhibit the mTOR pathway. To test this, A/J mice were treated with oral metformin after exposure to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Metformin reduced lung tumor burden by up to 53% at steady-state plasma concentrations that are achievable in humans. mTOR was inhibited in lung tumors but only modestly. To test whether intraperitoneal administration of metformin might improve mTOR inhibition, we injected mice and assessed biomarkers in liver and lung tissues. Plasma levels of metformin were significantly higher after injection than oral administration. In liver tissue, metformin activated AMPK and inhibited mTOR. In lung tissue, metformin did not activate AMPK but inhibited phosphorylation of insulin-like growth factor-I receptor/insulin receptor (IGF-1R/IR), Akt, extracellular signal-regulated kinase (ERK), and mTOR. This suggested that metformin indirectly inhibited mTOR in lung tissue by decreasing activation of insulin-like growth factor-I receptor/insulin receptor and Akt upstream of mTOR. Based on these data, we repeated the NNK-induced lung tumorigenesis study using intraperitoneal administration of metformin. Metformin decreased tumor burden by 72%, which correlated with decreased cellular proliferation and marked inhibition of mTOR in tumors. These studies show that metformin prevents tobacco carcinogen-induced lung tumorigenesis and support clinical testing of metformin as a chemopreventive agent.
Memmott
Regan M
RM
National Cancer Institute/Navy Medical Oncology, Room 5101, Building 8, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA.
Mercado
Jose R
JR
Maier
Colleen R
CR
Kawabata
Shigeru
S
Fox
Stephen D
SD
Dennis
Phillip A
PA
D000263:Adenylate Kinase / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D002273:Carcinogens; D002277:Carcinoma / Q000139:chemically induced / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008175:Lung Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D008687:Metformin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D009602:Nitrosamines; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D014026:Nicotiana / Q000009:adverse effects* / Q000737:chemistry
D000970:Antineoplastic Agents; D002273:Carcinogens; D007004:Hypoglycemic Agents; D009602:Nitrosamines; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; D008687:Metformin; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; D000263:Adenylate Kinase
J Clin Invest. 2007 May;117(5):1422-31
17476361
Oncogene. 2008 Jun 5;27(25):3576-86
18212742
J Nutr. 1993 Nov;123(11):1939-51
8229312
Cancer Res. 1989 Oct 1;49(19):5305-11
2670201
Nature. 2007 Aug 16;448(7155):807-10
17676035
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):215-9
15261814
Metabolism. 1995 May;44(5):645-51
7752914
Trends Mol Med. 2007 Oct;13(10):433-42
17905659
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35
14985505
Ann Intern Med. 2007 Sep 18;147(6):386-99
17638715
Carcinogenesis. 1989 Oct;10(10):1901-4
2791206
Science. 2005 Dec 9;310(5754):1642-6
16308421
Cancer Res. 2009 Sep 15;69(18):7439-48
19738076
Clin Cancer Res. 2007 Apr 1;13(7):2281-9
17404113
J Clin Invest. 2001 Oct;108(8):1167-74
11602624
Oncogene. 2007 Aug 30;26(40):5911-8
17384680
Ann Pharmacother. 1993 Oct;27(10):1183-7
8251683
Breast Cancer Res Treat. 2009 Jan;113(1):101-11
18256928
Clin Cancer Res. 2003 Aug 1;9(8):2998-3003
12912948
Endocrinology. 1992 Sep;131(3):1165-73
1505458
Cell Signal. 2009 May;21(5):656-64
19166931
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003053
19821299
Toxicol Appl Pharmacol. 1982 Jan;62(1):111-20
7064147
Biochem J. 2008 Jun 1;412(2):211-21
18387000
Cancer Cell. 2004 Jul;6(1):91-9
15261145
PLoS One. 2009;4(3):e5061
19330036
Gynecol Endocrinol. 2004 Sep;19(3):125-33
15697073
N Engl J Med. 1995 Aug 31;333(9):550-4
7623903
BMJ. 2005 Jun 4;330(7503):1304-5
15849206
Adv Ther. 2009 Oct;26(10):893-907
19921118
Diabetes Care. 2009 Sep;32(9):1620-5
19564453
Neurosci Lett. 2007 Jan 10;411(2):98-103
17110029
Nat Med. 2000 Sep;6(9):998-1003
10973319
Cancer Res. 2008 Jan 15;68(2):580-8
18199555
Endocr Relat Cancer. 2008 Sep;15(3):833-9
18469156
Cancer Res. 2007 Jul 15;67(14):6745-52
17638885
Cancer Res. 2007 Nov 15;67(22):10804-12
18006825
Clin Breast Cancer. 2008 Dec;8(6):501-5
19073504
Nat Rev Immunol. 2006 Apr;6(4):295-307
16557261